Premium
Octreotide therapy in asparaginase‐associated pancreatitis in childhood acute lymphoblastic leukemia
Author(s) -
Wu ShuFen,
Chen AnChyi,
Peng ChingTien,
Wu KangHsi
Publication year - 2008
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21721
Subject(s) - medicine , octreotide , asparaginase , pancreatitis , lymphoblastic leukemia , acute pancreatitis , gastroenterology , adverse effect , pediatrics , leukemia , somatostatin
Little is known about octreotide therapy in asparaginase‐associated pancreatitis (AAP) in children. Of the 59 children with acute lymphoblastic leukemia (ALL) receiving E. coli L ‐asparaginase, 5 patients (8.5%) developed AAP. Octreotide was administered to four patients. Clinical and laboratory improvement were evident after octreotide therapy. There were no deaths and no severe adverse side effects were noted. No pseudocysts were detected; however, two of the four patients developed diabetes. One child without octreotide treatment developed chronic pancreatitis and pseudocyst. We conclude that octreotide therapy appears to be safe and potentially beneficial in the management of AAP in children. Pediatr Blood Cancer 2008;51:824–825. © 2008 Wiley‐Liss, Inc.